Finance Watch: A SPACtacular Week For Biopharma Deals And Dollars
Executive Summary
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
You may also be interested in...
4D Pharma Joins The SPAC Trend To Fund Its Keytruda-Boosting Biotherapeutic
The Leeds, UK-based company is looking to the alternative route to the US stock market to fund its live biotherapeutics platform.
Coronavirus Update: Moderna’s Vaccine Shows Signs Of Lasting Protection
The US is to ship only half of doses for Pfizer, Moderna COVID-19 vaccines in the first instance, while Rhizen Pharmaceuticals starts a Phase I trial of a DHODH inhibitor.
Finance Watch: Joe Jimenez Ventures Into Start-Up World Via Aditum
Former Novartis CEO Jimenez co-founded Aditum with former NIBR president Mark Fishman; they raised $133m and are launching Tempero Bio. Also, Atea, Galecto and SQZ went public along with one more health care SPAC, Royalty Pharma upped its Vertex royalty revenues and Mirati’s FOPO raised $926.3m.
Need a specific report? 1000+ reports available
Buy Reports